LDC4297

LDC4297 is a selective inhibitor of CDK7 with an IC₅₀ value of 0.13 nM. LDC4297 inhibits human cytomegalovirus (HCMV) replication with an EC₅₀ value of 24.5 nM. LDC4297 shows broad antiviral activities to Herpesviridae, Adenoviridae, Poxviridae, Retroviridae and Orthomyxoviridae with EC₅₀ value of 0.02-1.21 μM. LDC4297 can be used for the research of infection^[1]. IC50 & Target:IC50: 0.13 nM (CDK7)^[1] In Vitro:LDC4297 (0-10 μM; 6 d) dose-dependently inhibits HCMV replication with an EC₅₀ value of 24.5 nM^[1].
LDC4297 (0-10 μM; 4 d) shows anti-proliferative activity to primary cultures of fibroblasts derived from human (HFF) with a GI₅₀ value of 4.5 μM^[1].
LDC4297 (20 μM; 12-96 h) shows anti-HCMV activity through a multifaceted mode of action that involves an interference with virus-induced Rb phosphorylation^[1].
LDC4297 (0-10 μM; 7 d) shows broad antiviral activities to HCMV, GPCMV, MCMV, HVV-6A, HSV-1, HSV-2, VZV, EBV, HAdV-2, Vaccinia virus, HIV-1 (nl4-3), HIV-1 (4LIG7) and Influenza A virus with EC₅₀ values of 0.02, 0.05, 0.07, 0.04, 0.02, 0.27, 0.06, 1.21, 0.25, 0.77, 1.04, 1.13 and 0.99 μM, respectively^[1]. In Vivo:LDC4297 (100 mg/kg; p.o. once) shows promising pharmacokinetic analyses^[1].